Regeneron/Sanofi dermatitis drug dupilumab dubbed 'breakthrough'
This article was originally published in Scrip
Executive Summary
The FDA has dubbed Regeneron Pharmaceuticals' and Sanofi's experimental atopic dermatitis drug dupilumab a breakthrough therapy – a status intended to expedite the regulatory process.